Previous 10 | Next 10 |
Summary Amarin continues to lose market share in the U.S. as it faces stiff competition from generic drug-makers. In Europe, AMRN may struggle to achieve the goal of getting reimbursement and launching in multiple countries without compromising on price. AMRN may face more than expe...
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the 41st Annual J.P. Morgan Healthcare Conference on January 10, ...
Amarin ( NASDAQ: AMRN ) said Swissmedic approved Vazkepa (icosapent ethyl) to reduce risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides and established cardiovascular disease, or diabetes and at least one other c...
-- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 -- -- Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland as its Regional Commercial Hub for Europe -- DUBLIN, Ireland and BRIDGEWATE...
Amarin Corporation plc (AMRN) 13th Annual Jefferies London Healthcare Conference 2022 November 16, 2022 9:40 a.m. ET Company Participants Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer Conference Call Participants ...
Commercial-stage biotech Amarin Corporation ( NASDAQ: AMRN ) announced Tuesday that the health regulators in Australia approved its fish oil-derived therapy Vascepa/Vazkepa to lower cardiovascular (CV) risk in certain patients with high lipid levels. The decision by the Th...
-- VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides -- -- Marks Fifth Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets in 2022 -- DUBLI...
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Jefferies London Healthcare Conference. The present...
Commercial-stage biotech Amarin Corporation ( NASDAQ: AMRN ) gained ~13% Monday, the highest intraday gain since June, after the company said that an independent study supported the benefit of purified eicosapentaenoic acid (EPA), a component in its heart disease therapy Vas...
-- Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients -- -- PROMINENT Study Failed to Show CV Risk Reduction Benefit of the Fibrate Class for Statin-Treated High-Risk Patients -- DUBL...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
2024-05-01 11:00:14 ET Image source: The Motley Fool. Amarin Plc (NASDAQ: AMRN) Q1 2024 Earnings Call May 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...